At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
Profounddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study to Evaluate the Safety and Efficacy Performance of the Profound System Using the Dermal and Sub-dermal (SubQ) Cartridges for the Treatment of Cellulite
In Brief
A clinical study evaluating Profound for Cellulite. Completed, enrolled 31 participants across 2 sites.
Detailed Summary
Clinical Study to Evaluate the Performance of the Profound System for the Treatment of Cellulite.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCellulite
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartSep 2017
Primary CompletionNov 2018
Study CompletionJan 2019
TodayJul 2026
First PostedMar 13, 2017
Enrollment StartSep 13, 2017
Primary CompletionNov 2, 2018
Study CompletionJan 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.3 years ago
Interventions
Profounddevice
The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.